Pharming Group N.V. — Investor Presentation 2009

Jun 3, 2009

PHARMING

PHARMING TO PRESENT AT UBS GLOBAL SPECIALTY PHARMACEUTICAL CONFERENCE 2009

Leiden, The Netherlands, June 2, 2009. Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) today announced that it will present at the UBS Global Specialty Pharmaceutical Conference (June 2-3, 2009) in London.

Sijmen de Vries, Chief Executive Officer of Pharming, will present on Wednesday, June 3 at 3 pm BST (4 pm CET). The presentation will be available on Pharming's website after the meeting. For further information on the UBS Global Specialty Pharmaceutical Conference and to listen to the audio webcast, please visit www.ibb.ubs.com.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® for Hereditary Angioedema and human lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, www.pharming.com.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact:

Sijmen de Vries, Pharming Group NV, T: +31 (0)71 52 47 400